NCT05327803Phase 2, phase 3Terminated

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

Study sponsor: AN2 Therapeutics, Inc · ANTX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-12-18Actual

Enrollment · participants177Actual

Source updated2026-06-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-10 · 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties; measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole; measure: Phase 2: Percentage of Participants Achieving Clinical Response; measure: Phase 3: Percentage of Participants Achieving Clinical Response

+ Updated value

measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole; measure: Phase 2: Percentage of Participants Achieving Clinical Response; measure: Phase 3: Percentage of Participants Achieving Clinical Response

The saved outcome text may be shortened. Check the source for full wording.

Check registry source

Posted 2026-05-01 · 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Phase 2: Assessment of novel Patient Reported Outcome instrument psychometric properties; measure: Phase 2: Percentage of Participants Achieving Clinical Response; measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole; measure: Phase 3: Percentage of Participants Achieving Clinical Response

+ Updated value

The saved outcome text may be shortened. Check the source for full wording.

Check registry source

Study details

Conditions studied

MAC Lung Disease; Treatment Refractory MAC Lung Disease

Treatments or interventions studied

EpetraboroleDrugAlso known as AN2-501971
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole; description: Percentage of Participants reporting treatment emergent adverse events; timeFrame: Baseline to Month 16; measure: Phase 2: Percentage of Participants Achieving Clinical Response; description: Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6 (Clinical Response measured as improvement in at least one symptom and no worsening in any others from baseline); timeFrame: Baseline to Month 6; measure: Phase 3: Percentage of Participants Achieving Clinical Response; description: Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6 (Clinical Response measured as improvement in at least one symptom and no worsening in any others from baseline); timeFrame: Baseline to Month 6

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history